The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Jun 2007 12:18

PuriCore Plc11 June 2007 TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES (1). Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached (ii): PuriCore PLC 2. Reason for the notification (please state Yes/No): ( ) An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) 3. Full name of person(s) subject to the notification obligation (iii): Newton Investment Management Limited 4. Full name of shareholder(s) (if different from 3.) (iv): Newton Investment Management Limited 5. Date of the transaction and date on which the threshold is crossed or reachedif different) (v): 18/05/07 6. Date on which issuer notified: 22/05/07 7. Threshold(s) that is/are crossed or reached: Decrease from 7.03% to 6.70% 8. Notified details: Sale 500,000 shares A: Voting rights attached to shares Class/type of shares Situation previous to if possible using the the Triggering ISIN CODE transaction (vi) Number of shares Number of voting Rights (viii) Ordinary 10,672,573 7.03%Shares ISINGB00B13TCY87 Resulting situation after the triggering transaction (vii) Class/type of shares Number of shares Number of voting rights % of voting rights if possible using (ix) the ISIN CODE Direct Direct (x) Indirect (xi) Direct Indirect Ordinary N/A N/A 10,172,573 N/A 6.70%Shares ISINGB00B13TCY87 B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Date Exercise/Conversion Number of voting % of voting financial (xiii) Period/ Date (xiv) rights that may be rights instrument acquired if the instrument is exercised/ converted. Total (A+B)Number of voting rights % of voting rights 10,172,573 6.70% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable (xv): Newton Investment Management Limited hold these shares as a discretionary Investment Manager. Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: 14. Contact name: Clare Cox / Barry Smalls 15. Contact telephone number: +44(0)207 163 2331 / 2251 Annex Notification Of Major Interests In Shares (XVI) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): Newton Investment Management Ltd Contact address (registered office for legal entities): Mellon Financial Centre160 Queen Victoria StreetLondon EC4V 4LA Phone number:+44(0)207 163 9000 Other useful information (at least legal representative for legal persons): Rachel Wheeler B: Identity of the notifier, if applicable (xvii) Full name: Newton Investment Management Ltd Contact address: Mellon Financial Centre160 Queen Victoria StreetLondon EC4V 4LA Phone number: +44(0)207 163 9000 Other useful information (e.g. functional relationship with the person or legalentity subject to the notification obligation): Discretionary Investment Manager C: Additional information : Notes to the Forms (i) This form is to be sent to the issuer or underlying issuer and to be filedwith the competent authority. (ii) Either the full name of the legal entity or another method for identifyingthe issuer or underlying issuer, provided it is reliable and accurate. (iii) This should be the full name of (a) the shareholder; (b) the personacquiring, disposing of or exercising voting rights in the cases provided for inDTR5.2.1 (b) to (h); (c) all the parties to the agreement referred to inDTR5.2.1 (a), or (d) the direct or indirect holder of financial instrumentsentitled to acquire shares already issued to which voting rights are attached,as appropriate. In relation to the transactions referred to in points DTR5.2.1 (b) to (h), thefollowing list is provided as indication of the persons who should be mentioned: - in the circumstances foreseen in DTR5.2.1 (b), the person that acquires thevoting rights and is entitled to exercise them under the agreement and thenatural person or legal entity who is transferring temporarily for considerationthe voting rights; - in the circumstances foreseen in DTR 5.2.1 (c), the person holding thecollateral, provided the person or entity controls the voting rights anddeclares its intention of exercising them, and person lodging the collateralunder these conditions; - in the circumstances foreseen in DTR5.2.1(d), the person who has a lifeinterest in shares if that person is entitled to exercise the voting rightsattached to the shares and the person who is disposing of the voting rights whenthe life interest is created; - in the circumstances foreseen in DTR5.2.1 (e), the parent undertaking and,provided it has a notification duty at an individual level under DTR 5.1, underDTR5.2.1 (a) to (d) or under a combination of any of those situations, thecontrolled undertaking; - in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of theshares, if he can exercise the voting rights attached to the shares depositedwith him at his discretion, and the depositor of the shares allowing the deposittaker to exercise the voting rights at his discretion; - in the circumstances foreseen in DTR5.2.1 (g), the person that controls thevoting rights; - in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he canexercise the voting rights at his discretion, and the shareholder who has givenhis proxy to the proxy holder allowing the latter to exercise the voting rightsat his discretion. (iv) Applicable in the cases provided for in DTR 5.2.1 (b) to (h). This shouldbe the full name of the shareholder who is the counterparty to the naturalperson or legal entity referred to in DTR5.2. (v) The date of the transaction should normally be, in the case of an onexchange transaction, the date on which the matching of orders occurs; in thecase of an off exchange transaction, date of the entering into an agreement. The date on which threshold is crossed should normally be the date on which theacquisition, disposal or possibility to exercise voting rights takes effect (seeDTR 5.1.1R (3)). For passive crossings, the date when the corporate event tookeffect. (vi) Please refer to the situation disclosed in the previous notification, Incase the situation previous to the triggering transaction was below 3%, pleasestate 'below 3%'. (vii) If the holding has fallen below the minimum threshold , the notifyingparty should not be obliged to disclose the extent of the holding, only that thenew holding is less than 3%. For the case provided for in DTR5.2.1(a), there should be no disclosure ofindividual holdings per party to the agreement unless a party individuallycrosses or reaches an Article 9 threshold. This applies upon entering into,introducing changes to or terminating an agreement. (viii) Direct and indirect (ix) In case of combined holdings of shares with voting rights attached 'directholding' and voting rights 'indirect holdings', please split the voting rightsnumber and percentage into the direct and indirect columns-if there is nocombined holdings, please leave the relevant box blank. (x) Voting rights to shares in respect of which the notifying party is a directshareholder (DTR 5.1) (xi) Voting rights held by the notifying party as an indirect shareholder (DTR5.2.1) (xii) If the holding has fallen below the minimum threshold, the notifying partyshould not be obliged to disclose the extent of the holding, only that the newholding is below 3%. (xiii) date of maturity / expiration of the finical instrument i.e. the datewhen the right to acquire shares ends. (xiv) If the financial instrument has such a period-please specify the period-for example once every three months starting from the (date) (xv) The notification should include the name(s) of the controlled undertakingsthrough which the voting rights are held. The notification should also includethe amount of voting rights and the percentage held by each controlledundertaking, insofar as individually the controlled undertaking holds 5% ormore, and insofar as the notification by the parent undertaking is intended tocover the notification obligations of the controlled undertaking. (xvi ) This annex is only to be filed with the competent authority. (xvii) Whenever another person makes the notification on behalf of theshareholder or the natural person/legal entity referred to in DTR5.2 and DTR5.3 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th Oct 20185:02 pmRNSForm 8.3 - Realm Therapeutics PLC
9th Oct 201810:13 amRNSForm 8.3 - Realm Therapeutics plc
5th Oct 20186:08 pmBUSForm 8.3 - Realm Therapeutics PLC
5th Oct 20182:00 pmRNSFORM 8.3 - Realm Therapeutics Plc
4th Oct 20188:57 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics plc
2nd Oct 201810:43 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics PLC
1st Oct 20187:00 amRNSProvides Update on Timing of Formal Sale Process
24th Sep 20189:59 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Sep 201811:33 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20185:06 pmRNSForm 8.3 - Realm Therapeutics plc
20th Sep 20183:16 pmRNSHolding(s) in Company
20th Sep 201811:53 amRNSForm 8.3 - REALM THERAPEUTICS PLC
20th Sep 201811:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Sep 20184:31 pmRNSForm 8 (OPD) - Realm Therapeutics plc
19th Sep 201811:11 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
18th Sep 201811:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Sep 20187:00 amRNSCorporate Update and Hiring of Advisor
20th Aug 201811:00 amRNSPrice Monitoring Extension
20th Aug 20187:00 amRNSBlock listing Interim Review
15th Aug 20184:35 pmRNSPrice Monitoring Extension
14th Aug 20187:10 amRNSHalf-year Report
8th Aug 20187:00 amRNSPresents at Wedbush PacGrow Healthcare Conference
7th Aug 20187:00 amRNSNotice of Results
16th Jul 20185:33 pmRNSHolding(s) in Company
10th Jul 20187:00 amRNSPre-Clinical Study in Atopic Dermatitis
4th Jul 20187:00 amRNSInstructions for Exchanging Ordinary Shares
4th Jul 20187:00 amRNSSEC registration effective NASDAQ listing approved
14th Jun 201810:54 amRNSResult of AGM
31st May 20187:00 amRNSRealm to Present at June Investor Conferences
24th May 20187:00 amRNSEnrollment complete for Phase 2 study of PR022
23rd May 20187:00 amRNSFiling with US SEC to Facilitate Nasdaq Listing
21st May 20187:00 amRNSData Presentation at IID 2018
2nd May 201812:39 pmRNSAnnual Financial Report Available
2nd May 20187:00 amRNSFinal Results
2nd May 20187:00 amRNSRealm Files Registration for Nasdaq Listing of ADS
26th Apr 20182:32 pmRNSNotice of Results
12th Mar 20184:40 pmRNSSecond Price Monitoring Extn
12th Mar 20184:35 pmRNSPrice Monitoring Extension
12th Mar 20187:00 amRNSClinical Update including PR013 Phase II results
8th Mar 20187:00 amRNSPresenting at Cowen Healthcare Conference
27th Feb 20187:00 amRNSPatent portfolio strengthened with USPTO allowance
20th Feb 201812:00 pmRNSPresentation at RBC Healthcare Conference
16th Feb 20187:00 amRNSBlock listing Interim Review
15th Feb 20187:00 amRNSClinical and Business Update
2nd Jan 20187:00 amRNSPresents at 5th Annual Dermatology Summit
15th Dec 20177:00 amRNSDirector/PDMR Shareholding
12th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR013
5th Dec 20177:00 amRNSFirst Patient Dosed in Phase 2 Study of PR022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.